Unanswered Questions in Pediatric HS

The group addresses lingering research questions and stresses the importance of disease education in order to meet the needs of Hidradenitis Suppurativa (HS) patients. Consensus guidelines exist for adult HS but have yet to be written for pediatric HS. The need for early diagnosis is not only critical for disease management but is vital for the overall well-being of patients and their families.  

Aggressive Options for Pediatric HS

Dr. Lara-Corrales and Dr. Izzy Andrews discuss aggressive treatments for Hidradenitis Suppurativa (HS) and highlight the importance of a multi-disciplinary care team to help treat the psychosocial aspects and the physical pain associated with this traumatic disease. Access to care is also a key component in combating HS and it’s critical that more than just pediatric dermatologists have a better understanding of HS before treating patients.

Non-Aggressive Options for Pediatric HS

Dr. Irene Lara-Corrales and Dr. Yasmine Kirkorian discuss non-aggressive treatment options available to pediatric patients with Hidradenitis Suppurativa (HS) and how difficult it can be to quantify just exactly what it means when providers recommend “lifestyle” changes to help treat this devastating inflammatory skin disease.

Dr. Carrie Coughlin is an Assistant Professor of Dermatology at Washington University School of Medicine in St. Louis. She is the chair of the PeDRA Outcomes Committee, serves on the PeDRA Meetings and Studies committees, and leads the Skin Tumors and Reactions to Cancer Therapies (STARC) Focused Study Group. Learn more about Dr. Coughlin and the importance of communicating PeDRA’s work outside the field of pediatric dermatology.

This year marks PeDRA’s 10th anniversary. For 10 years, our vibrant community has been forging relationships and conducting meaningful research to prevent, treat, and cure childhood skin diseases. Together, we are advancing the field in ways that were nothing more than dreams 10 years ago. Take a look back at what we’ve accomplished and where we’re heading in the future with PeDRA’s Executive Director, Mike Siegel, PhD.

Exciting New Research

In this final episode, the group discusses current research efforts and the research that is still needed to better understand the long-term-use effects of immune modulators, and how to approach conversations about using these medications with both patients and families.  

If you are interested in or have patients you would like to enroll in the University of Colorado Immune Skin Conditions Clinical Trial, please click here for more information.

The Pros and Cons of Immune Modulators

The group weighs the pros and cons of using immune modulators, and how to manage concerns and expectations in the exam room with both patients and parents.

An Overview of Skin Diseases Seen in Children with Down Syndrome

Moderated by Jillian Rork, MD, the group discusses the skin conditions in children with Down syndrome that require treatment with immune modulators.

Dr. Harper Price is the Division Chief and Fellowship Director of Pediatric Dermatology at Phoenix Children’s Hospital as well as Clinical Assistant Professor at the University of Arizona College of Medicine. Having been a member of PeDRA since nearly the beginning, she’s previously served on the Membership Committee and is currently serving on the Grants Committee and PeDRA’s Best Practices Task Force. Dr. Price is an avid photographer and loves animals. Watch to learn more about her great work.

In this PeDRA Early Investigator webinar, Gail Gazelle, MD, teaches about the neuroscience of Imposter Syndrome, who it affects, why and how it develops, and practical strategies to leave it behind! 

Click here to download an imposter syndrome worksheet.